BERLIN and MUNICH—Global pharmaceutical company and service partner Inceptua Group (previously known as Multipharma GmbH) and Bendalis GmbH, a German manufacturer of generic oncology drugs and special therapeutic agents, announced today the signing of an exclusive clinical trial supply agreement for oncology generics.
Through this agreement Inceptua will become the exclusive distributor of Bendalis’ products for their use in clinical trials worldwide. Inceptua will offer clinical trial sponsors quick access to Brexit-safe oncology standard-of-care medicines which are produced within the European Union.
“With this agreement Bendalis and Inceptua join forces to ensure optimal sourcing and supply of medicines for use in oncology clinical trials to our clients,” said Alan Raffensperger, CEO of Inceptua. “Together, we share a mission to provide uninterrupted access for patients to high quality products through a secure and robust supply chain.”
As part of the agreement, Bendalis will maintain stock of specific products on a consignment basis, offering Inceptua’s clients “on-demand” access. Even the most well planned clinical trials may experience supply challenges at some point, and operating a consignment model provides contingency against manufacturing issues, stock-out situations and mitigation of study delays which would impact both patients and sponsors.
Through this agreement, Inceptua adds to the broad range of oncology comparators and standard-of-care medicines it already supplies for clinical trial use with exclusive access to Bendalis’ portfolio of products, which are commonly used in chemotherapy. These products include carboplatin, docetaxel, gemcitabine, paclitaxel, oxaliplatin, vinorelbine, irinotecan and fluorouracil (5FU).
“In the oncology space we experience a growing need and demand for products. We see Inceptua as the ideal partner to handle the distribution and help optimize the clinical trial supply for clients. A consistent and secure supply of products is a critical component in clinical trials, and together we can offer a flexible yet reliable solution, helping clients minimize overage and reduce costs,” added Christian Parvany, CEO of Bendalis.